Boehringer signs deal for Owkin AI in drug discovery
Boehringer Ingelheim agreed to use Owkin's AI model to help discover new oncology and immunology medicines, joining AstraZeneca and Sanofi in similar partnerships.
1 source
Health by email
Get an email when there's news on Health
No news that day, no email.
More stories today
- NYSE used Anthropic's Project Glasswing to find cyber flaws
- Cloudflare CEO says ready to block AI crawlers from millions of sites
- Napster CEO: Microsoft helps reinvent company with agentic AI
- Google shares 4 engineering patterns from AI Agents Challenge
- Anthropic launches commerce agent blueprint for Claude